Skip to main content
RCELAvita Medical, Inc.Sell4.9·$16.59

Avita Medical (RCEL) Q3 2026 earnings — TrendMatrix coverage

IN LINE+1.8% vs estimateEPS -$0.29 vs -$0.29 estCurrent verdict Sell 4.9/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
-$0.29
Estimate
-$0.29
Surprise
+1.8%
Revenue (period 2026-09-30)
$26.1M
Score today
4.9/10

Revenue source: xbrl.

Report record · Q3 2026

How the report landed

Avita Medical (RCEL) reported adjusted EPS of -$0.29, in line with the -$0.29 estimate.

Around the report

Coverage in the report window

  • Lake Street Maintains Buy on AVITA Medical, Raises Price Target to $20 — benzinga, 2026-11-06
  • AVITA Medical Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance — fiscal.ai, 2026-11-06
  • Texas Roadhouse To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Friday — benzinga, 2026-11-06
Current read · as of 2026-11-07

Where TrendMatrix's rating stands now

TrendMatrix currently rates RCEL Sell at 4.9/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +1.8% surprise compares with a -3.7% four-quarter average. Next scheduled report: 2027-02-11.

What argues against it

  • Concentration risk — Regulatory: FDA PMA approval for RECELL
  • Concentration risk — Supplier: single-sourced material components
  • Target reached (-32.1% upside)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$16.59
Stop
$15.43

Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 2.3× its average — elevated turnover around the report window.

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare context

RCEL at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Devices
Market cap
$519.5M
P/E (fwd)
-39.0
52-week range
$3.22–$18.00
Off 52-week high
7.8%
RSI (14)
71
Volume vs avg
2.25×
Score today
4.9/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › RCEL › Earnings › Q3 2026 earnings